Phaseline

Companies › Ellipses Pharma

Ellipses Pharma: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EP0031 (Lunbotinib)
RET inhibitor
RETPhase 1NSCLCMar 2027
EP0042–Phase 1Acute Myeloid LeukemiaDec 2027
EP0062
Selective androgen receptor modulator (SARM)
ARPhase 1Hormone Receptor-positive Breast CancerFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05443126EP0031 (Lunbotinib)Phase 1NSCLCOncologyMar 2027
NCT04581512EP0042Phase 1Acute Myeloid LeukemiaOncologyDec 2027
NCT05573126EP0062Phase 1Hormone Receptor-positive Breast CancerOncologyFeb 2028

Targets

RET (1) AR (1)

Companies with the same targets

Roche Eli Lilly Johnson & Johnson (Janssen) Novartis Astellas Alessa Therapeutics Sun Pharmaceutical Industries Beijing Scitech-Mq Pharmaceuticals Taiho Pharmaceutical Jiangsu Hansoh Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.